

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quemliclustat
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Taiho Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Quemliclustat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Pancreatic Ductal.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 23, 2024
Lead Product(s) : Quemliclustat
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Taiho Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quemliclustat,Etrumadenant,Zimberelimab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Taiho Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Taiho Exercises License Option for Quemliclustat in Japan and Asia
Details : Under the license agreement, Taiho will further support the development & commercialization of AB680 (quemliclustat) & will operationalize the PRISM-1 study in Japan as part of its mission.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 08, 2024
Lead Product(s) : Quemliclustat,Etrumadenant,Zimberelimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Taiho Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quemliclustat,Paclitaxel,Zimberelimab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Quemliclustat-Based Regimens Show Promising Survival in Metastatic Pancreatic Cancer
Details : AB680 (quemliclustat) is an investigational small molecule CD73 inhibitor in phase 1 development, evaluated in combination with chemotherapy for treatment-naïve metastatic pancreatic cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : Quemliclustat,Paclitaxel,Zimberelimab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quemliclustat,Paclitaxel,Zimberelimab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Quemliclustat-Based Regimens Show Survival Promise in Metastatic Pancreatic Cancer
Details : AB680 (quemliclustat) is an investigational CD73 inhibitor undergoing phase 1 trials in combination with zimberelimab and chemotherapy for metastatic pancreatic cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : Quemliclustat,Paclitaxel,Zimberelimab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quemliclustat
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Catherine Spina
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Quemliclustat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 23, 2023
Lead Product(s) : Quemliclustat
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Catherine Spina
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quemliclustat,Paclitaxel,Zimberelimab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preliminary data from the first dose-escalation cohorts, reported in an abstract released today, demonstrate encouraging signs of clinical activity for AB680 in combination with zimberelimab (anti-PD-1 antibody) and chemotherapy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 11, 2021
Lead Product(s) : Quemliclustat,Paclitaxel,Zimberelimab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quemliclustat
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers
Details : AB680 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 05, 2020
Lead Product(s) : Quemliclustat
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quemliclustat
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AB680 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 26, 2019
Lead Product(s) : Quemliclustat
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quemliclustat
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Investigate the Safety of AB680 in Healthy Volunteers
Details : AB680 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 19, 2018
Lead Product(s) : Quemliclustat
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
